Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note released on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock.

A number of other brokerages also recently commented on GANX. BTIG Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Gain Therapeutics Stock Down 1.2%

Shares of Gain Therapeutics stock opened at $1.69 on Monday. The stock has a 50-day moving average price of $1.83 and a 200 day moving average price of $1.83. The company has a market cap of $73.75 million, a P/E ratio of -3.38 and a beta of 0.19. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 1 year low of $1.53 and a 1 year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, analysts expect that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Potomac Capital Management Inc. acquired a new position in Gain Therapeutics in the 4th quarter valued at $3,252,000. GSA Capital Partners LLP bought a new position in Gain Therapeutics in the 2nd quarter worth $1,283,000. BlackRock Inc. acquired a new position in Gain Therapeutics during the 2nd quarter worth $558,000. Squarepoint Ops LLC bought a new stake in Gain Therapeutics during the second quarter valued at about $277,000. Finally, Apollon Wealth Management LLC boosted its holdings in Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock valued at $51,000 after acquiring an additional 6,675 shares during the period. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.